Johnson & Johnson (J&J) has proposed a settlement of up to $5.5 billion to resolve tens of thousands of lawsuits in the United States alleging that its talc-based baby powder and related products caused ovarian cancer. The proposed agreement marks the company’s latest effort to bring an end to one of the most significant legal disputes in its history.

The New Jersey-based healthcare giant said the settlement is intended to provide a comprehensive resolution to claims that have weighed on the company for years. Despite the offer, J&J continues to reject allegations that its talc-based products are linked to cancer, maintaining that the lawsuits lack scientific merit.

Settlement Hinges on Broad Legal Support

Under the proposal, Johnson & Johnson plans to pay up to $3 billion next year, with no additional payments scheduled before 2028. However, the agreement will only move forward if legal firms representing at least 95% of the ovarian cancer claims in state and federal courts agree to the settlement terms.

Erik Haas, J&J’s Vice President of Litigation, described the allegations as “meritless,” emphasizing that the company is pursuing a settlement to finally close the long-running litigation rather than because it believes the claims are valid.

Haas said the company remains confident it would have ultimately prevailed through continued litigation, pointing to favorable outcomes in the majority of cases that have reached trial. He added that resolving the issue would allow Johnson & Johnson to fully focus on its core mission of developing life-saving medicines and medical technologies.

Long-Running Talc Litigation

Legal claims against Johnson & Johnson over its talc-based baby powder date back to 2009, with thousands of consumers alleging that prolonged use of the products led to ovarian cancer due to asbestos contamination.

Talc is a naturally occurring mineral composed of magnesium, silicon, oxygen, and hydrogen. Because talc deposits are often located near asbestos, critics have argued that contamination during mining could expose consumers to the known carcinogen J And J has consistently denied these allegations, stating that extensive scientific research demonstrates its talc products are safe, asbestos-free, and do not cause cancer.

Earlier this month, the company secured a legal victory after a federal court questioned whether individual plaintiffs could sufficiently establish that talc directly caused their ovarian cancer, strengthening J&J’s legal position.

Business Restructuring and Future Focus

J And J has also restructured its consumer health business. In 2022, it spun off Kenvue, the company behind brands such as Band-Aid, Listerine, and Calpol. Kenvue now assumes liability for Johnson’s Baby Powder products sold outside North America.

If approved, the proposed settlement could finally bring closure to one of the largest product liability disputes in the healthcare industry’s history, allowing J And J to move beyond years of litigation while continuing to defend the safety of its talc-based products.

Also Read :- Global Cancer Cases Expected to Surge to 35 Million by 2050, Warns WHO Report